Hypertension
According to the 1st WHO Global report 2023 on hypertension, hypertension remains a significant public health concern, contributing to the onset of cardiovascular diseases, stroke, and premature death. Only 54% of adults with hypertension are diagnosed, 42% receive treatment, and a mere 21% have their hypertension controlled.
There are approximately 1.28 billion hypertension patients in the world. In US, nearly half of adults have hypertension (119.9 million) and only about 1 in 4 adults with hypertension have their hypertension under control (27.0 million). Many adults who are already treated with antihypertensive medication(s) may need to have their current medication dosage increased or to be prescribed additional medications to achieve blood pressure control (33.2 million). More than half of this group have blood pressure ≥140/90 mm Hg (18.8 million). Furthermore, there are approximately 245 million hypertension patients in China. Epidemiological surveys show that the awareness rate, treatment rate and control rate of hypertension in China are 51.6%, 45.8% and 16.8%, respectively, which are all relatively low.
The Renin-Angiotensin-Aldosterone System plays a critical role to regulate the fluids and electrolytes balances in humans. Inhibition of aldosterone synthase has been proven effective at clinical setting for numerous cardiometabolic diseases.
JX09 is a next-generation, highly selective aldosterone synthase inhibitor. Preclinical data suggest that JX09 offers strong potency inhibiting aldosterone synthase, with very little impact on the biological functions of a homologous enzyme that is key to cortisol synthesis. The high potency and selectivity make JX09 a potential best-in-class drug candidate.
In February 2023, CORXEL obtained global rights to JX09 from PhaseBio Pharmaceuticals, Inc. In February 2024, CORXEL announced the successful dosing of the first subject in the Phase I clinical trial of the cardiovascular investigational product JX09 (formerly PB6440) in Australia
Reference:
• Lee J, Schotzinger J, et al. The Selective Aldosterone Synthase Inhibitor PB6440 Normalizes Blood Pressure In A Human Aldosterone Synthase-Transgenic Mouse Model Of Hypertension, Hypertension 2022, 79, A121.
• Pitt B, Bhatt D, et al, Inhibition Of Aldosterone Synthesis In Non-human Primates By PB6440, The Novel Highly Selective And Potent CYP11B2 Inhibitor, Hypertension 2020, 76, AP233.
• NCD Risk Factor Collaboration (NCD-RisC), Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants, The Lancet 2021, 398, 10304, 957-980.
• Kario, K., Okura, A., Hoshide, S. et al. The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res 47, 1099–1102 (2024). https://doi.org/10.1038/s41440-024-01622-w
• National Center for Cardiovascular Diseases, et al. Clinical practice guidelines for the management of hypertension in China. China J Cardiol, 2022, 50(11): 1050-1095.
• Wang Z, Chen Z, Zhang L, et al. Status of Hypertension in China: results from the China hypertension survey, 2012– 2015. Circulation 2018; 137: 2344–2356.
• https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html
